59 related articles for article (PubMed ID: 11877305)
1. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.
Kennedy B; Rawstron A; Carter C; Ryan M; Speed K; Lucas G; Hillmen P
Blood; 2002 Mar; 99(6):2245-7. PubMed ID: 11877305
[TBL] [Abstract][Full Text] [Related]
2. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
Zent CS; Call TG; Shanafelt TD; Tschumper RC; Jelinek DF; Bowen DA; Secreto CR; Laplant BR; Kabat BF; Kay NE
Cancer; 2008 Oct; 113(8):2110-8. PubMed ID: 18759253
[TBL] [Abstract][Full Text] [Related]
3. Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras CH; Siakantaris MP
Med Oncol; 2000 Feb; 17(1):70-3. PubMed ID: 10713664
[TBL] [Abstract][Full Text] [Related]
4. Management of chronic lymphocytic leukemia.
Ghia P; Hallek M
Haematologica; 2014 Jun; 99(6):965-72. PubMed ID: 24881042
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use.
Warner JL; Arnason JE
Ther Adv Hematol; 2012 Dec; 3(6):375-89. PubMed ID: 23606939
[TBL] [Abstract][Full Text] [Related]
7. Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders.
Cassano C; Mactier S; Mulligan SP; Belov L; Huang P; Christopherson RI
Int J Proteomics; 2010; 2010():964251. PubMed ID: 22084681
[TBL] [Abstract][Full Text] [Related]
8. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Parikh SA; Keating MJ; O'Brien S; Wang X; Ferrajoli A; Faderl S; Burger J; Koller C; Estrov Z; Badoux X; Lerner S; Wierda WG
Blood; 2011 Aug; 118(8):2062-8. PubMed ID: 21750315
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
[TBL] [Abstract][Full Text] [Related]
10. Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.
Montagna M; Montillo M; Avanzini MA; Tinelli C; Tedeschi A; Visai L; Ricci F; Vismara E; Morra E; Regazzi M
Haematologica; 2011 Jun; 96(6):932-6. PubMed ID: 21330330
[TBL] [Abstract][Full Text] [Related]
11. Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?
Varghese AM; Rawstron AC; Hillmen P
Curr Hematol Malig Rep; 2010 Jan; 5(1):35-44. PubMed ID: 20425395
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging treatments for chronic lymphocytic leukaemia.
Robak T; Jamroziak K; Robak P
Drugs; 2009; 69(17):2415-49. PubMed ID: 19911856
[TBL] [Abstract][Full Text] [Related]
13. Antibody-based therapy of leukaemia.
Morris JC; Waldmann TA
Expert Rev Mol Med; 2009 Sep; 11():e29. PubMed ID: 19788782
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).
Montillo M; Ricci F; Miqueleiz S; Tedeschi A; Morra E
Biologics; 2008 Mar; 2(1):41-52. PubMed ID: 19707426
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.
Angiolillo AL; Yu AL; Reaman G; Ingle AM; Secola R; Adamson PC
Pediatr Blood Cancer; 2009 Dec; 53(6):978-83. PubMed ID: 19637330
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
Motta M; Wierda WG; Ferrajoli A
Cancer; 2009 Sep; 115(17):3830-41. PubMed ID: 19536902
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine in the treatment of chronic lymphocytic leukemia: a review.
Ricci F; Tedeschi A; Morra E; Montillo M
Ther Clin Risk Manag; 2009 Feb; 5(1):187-207. PubMed ID: 19436622
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab in the up-front setting.
Kaufman M; Rai KR
Ther Clin Risk Manag; 2008 Apr; 4(2):459-64. PubMed ID: 18728844
[TBL] [Abstract][Full Text] [Related]
19. Antibody therapy for chronic lymphocytic leukemia.
Christian BA; Lin TS
Semin Hematol; 2008 Apr; 45(2):95-103. PubMed ID: 18381104
[TBL] [Abstract][Full Text] [Related]
20. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.
Robak T
Drugs Aging; 2005; 22(12):983-1012. PubMed ID: 16363884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
